BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Clinical Outcome
312 results:

  • 1. Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
    Fontanges Q; Dubos P; Lesluyes T; Laizet Y; Velasco V; Meléndez B; D'Haene N; Oliva E; Young RH; Mayeur L; Rebier F; Alamé M; Larmonier C; Devouassoux-Shisheboran M; Arnould L; Soubeyran I; Chakiba C; Floquet A; Babin G; Guyon F; Mery E; Le Guellec S; Noël JC; Croce S; Chibon F
    Genes Chromosomes Cancer; 2024 Mar; 63(3):e23229. PubMed ID: 38481055
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Impact of histological subtypes on clinical outcome of endocervical adenocarcinoma.
    Tian X; Liu P; Kang S; Cui Z; Sun L; Lang J; Chen C
    Eur J Surg Oncol; 2024 Apr; 50(4):107977. PubMed ID: 38373385
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.
    Chang HY; Dermawan J; Sharma A; Dickson B; Turashvili G; Torrence D; Nucci M; Chiang S; Oliva E; Kirchner M; Stenzinger A; Mechtersheimer G; Antonescu C
    Mod Pathol; 2024 Feb; 37(2):100402. PubMed ID: 38141829
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. outcome prediction for symptomatic patients with fibroids who underwent uterine artery embolization.
    Wu Q; Motaghi M; Tang H; Hazhirkarzar B; Shaghaghi M; Ghadimi M; Baghdadi A; Rezvani R; Mohseni A; Borhani A; Madani SP; Afyouni S; Zandieh G; Kamel IR
    Clin Imaging; 2024 Jan; 105():110028. PubMed ID: 38039750
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK.
    Evans I; Reisel D; Jones A; Bajrami A; Nijjar S; Solangon SA; Arora R; Redl E; Schreiberhuber L; Ishaq-Parveen I; Rothärmel J; Herzog C; Jurkovic D; Widschwendter M
    Lancet Oncol; 2023 Dec; 24(12):1375-1386. PubMed ID: 37944542
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients.
    Bolaños-Suárez V; Alfaro A; Espinosa AM; Medina-Martínez I; Juárez E; Villegas-Sepúlveda N; Gudiño-Zayas M; Gutiérrez-Castro A; Román-Bassaure E; Salinas-Nieves ME; Bruno-Muñoz S; Aranda C; Flores-Herrera O; Berumen J
    Cancer Med; 2023 Jul; 12(14):15632-15649. PubMed ID: 37326348
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer.
    Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H
    BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
    Reijnen C; Vrede SW; Eijkelenboom A; Draak R; Sweegers S; Snijders MPLM; van Gestel P; Pijnenborg JMA; Bulten J; Küsters-Vandevelde HVN
    Cancer Med; 2023 Jun; 12(11):12365-12376. PubMed ID: 37081760
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
    Madariaga A; Garg S; Tchrakian N; Dhani NC; Jimenez W; Welch S; MacKay H; Ethier JL; Gilbert L; Li X; Rodriguez A; Chan L; Bowering V; Clarke B; Zhang T; King I; Downs G; Stockley T; Wang L; Udagani S; Oza AM; Lheureux S
    Nat Commun; 2023 Mar; 14(1):1452. PubMed ID: 36922497
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study.
    Song S; Han D; Zhang N; Mao Z; Guo X; Cheng G
    Radiat Oncol; 2023 Mar; 18(1):46. PubMed ID: 36879287
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. clinical outcome analysis of intramural myoma greater than 8 cm in diameter removed during caesarean section: a retrospective study.
    Shi C; Chen J; Chen A
    BMC Womens Health; 2023 Feb; 23(1):60. PubMed ID: 36774454
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. uterine Myoma Position-based Radiofrequency Ablation (UMP-b RFA): 36 months follow-up clinical outcomes.
    Fasciani A; Turtulici G; Pedullà A; Sirito R
    Eur J Obstet Gynecol Reprod Biol; 2023 Feb; 281():23-28. PubMed ID: 36527825
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: clinical outcome and prognostic factors.
    Ka K; Laville A; Rassy E; Ayachi RE; Pautier P; Ba MB; Bockel S; Achkar S; Espenel S; Maulard A; Morice P; Gouy S; Haie-Meder C; Sun R; Chargari C
    Gynecol Oncol; 2023 Jan; 168():32-38. PubMed ID: 36370612
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Relevance of High Temperatures and Short Time Intervals Between Radiation Therapy and Hyperthermia: Insights in Terms of Predicted Equivalent Enhanced Radiation Dose.
    Kok HP; Herrera TD; Crezee J
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):994-1003. PubMed ID: 36288756
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
    López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
    J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer.
    Rogowski P; Rottler M; Walter F; Saicic S; Niyazi M; Well J; Nierer L; Trillsch F; Burges A; Mahner S; Belka C; Corradini S
    Gynecol Oncol; 2022 Sep; 166(3):576-581. PubMed ID: 35764443
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
    Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
    J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. High-grade Endometrial Stromal Sarcoma: Morphologic and clinical Features, the Role of Immunohistochemistry and Fluorescence in Situ Hybridization in Diagnosis.
    Alkanat NE; Uner A; Usubutun A
    Int J Surg Pathol; 2023 Aug; 31(5):521-531. PubMed ID: 35506912
    [No Abstract]    [Full Text] [Related]  

  • 19. clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience.
    Kim MS; Jeong SY; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
    Taiwan J Obstet Gynecol; 2022 Mar; 61(2):333-338. PubMed ID: 35361397
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy.
    Zeng J; Sun P; Ping Q; Jiang S; Hu Y
    PLoS One; 2022; 17(3):e0266001. PubMed ID: 35324998
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 16.